Overview
- Gilead will pay $115 per share in cash plus a $5 contingent value right tied to anito-cel reaching $6 billion in cumulative global sales by the end of 2029.
- The companies expect the transaction to close in the second quarter of 2026, and Gilead already owns roughly 11.5% of Arcellx.
- Anito-cel is being evaluated as a fourth-line treatment for relapsed or refractory multiple myeloma, with the BLA supported by the pivotal iMMagine-1 study.
- Pivotal data reported an independent review committee–assessed overall response rate of 96% and stringent complete or complete responses in 74%, with high rates of MRD negativity.
- Gilead projects the deal to be accretive to earnings per share starting in 2028 upon approval, and Arcellx shares jumped about 78% on the news while Gilead dipped roughly 1%.